Hosted on MSN23h
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital ...
News Medical on MSN37m
Breakthrough microscopy technique reveals how antibodies target cancer cells
Professor Markus Sauer from the Biocentre of Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany ...
GlobalData on MSN2d
FDA awards GSA breakthrough status for relapsed osteosarcoma treatment
GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
조선일보2d
Korea's Resolute gains FDA breakthrough therapy designation for RZ358 treatment
Koreas Resolute gains FDA breakthrough therapy designation for RZ358 treatment Resolute receives FDA recognition for ...
Drug breakthrough offers hope for advanced prostate cancer patients
Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...
Cancer Therapy Advisor2d
Novel Antibody-Drug Conjugate Gets Breakthrough Tx Designation for Rel/Ref Osteosarcoma
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.
Cure Today19h
FDA Grants BTD to the ADC GSK’227 in Relapsed/Refractory Osteosarcoma
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...
Targeted Oncology2d
FDA Grants B7-H3–Targeted ADC Breakthrough Status in Osteosarcoma
The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821). On January 8, 2025, ...